Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13255 – 13270
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6234

Candida Auris: An Updated Review for Nursing Interventions and Management Protocols

AMNAH Ali Otayn[1], Hanem Adel Abdullah Alnasser[2], ADNAN MUSA ALZAHRANI[3], Noha Muaybid Alharbi[4], Amnah Ahmad Aseri[5], Ibrahim Mohammed Mahzari[6], Mubarak Juhayyim Mohammed Alosaimi[7], IBRAHIM AYIDH ALOTAIBI[8], Gosnh Saad AL-Hareegi[9], Jehan Abdullah Mohammad Alabyad[10], Ghadeer Mohammad Eid Almohammady[11], DHAIFALLAH MUBARAK EID ALAZMI[12], Dalal Nukhaylan Duwaylan Almutairi[13], Hadiayah Faisal Sultan Almutiri[14], Shadia Lafi Almutairi[15]

Abstract

Candida auris (C. auris) is an emerging multidrug-resistant fungal pathogen that poses a significant global health threat, particularly in healthcare settings. First identified in 2009, C. auris has rapidly spread to over 35 countries, causing invasive infections with high mortality rates, especially among immunocompromised patients. Its resistance to multiple antifungal classes, misidentification by standard diagnostic methods, and ability to persist on surfaces complicate its management and control.This review aims to provide an updated overview of C. auris, focusing on its epidemiology, pathophysiology, resistance mechanisms, and clinical management. It also highlights the critical role of nursing interventions and infection control protocols in preventing and managing C. auris outbreaks.The review synthesizes current literature on C. auris, including its etiology, transmission patterns, virulence factors, and antifungal resistance mechanisms. It also examines diagnostic challenges, treatment strategies, and nursing management protocols. Emphasis is placed on infection control measures, such as hand hygiene, environmental disinfection, and patient isolation, to mitigate the spread of C. auris in healthcare settings.C. auris is highly transmissible in nosocomial environments, with resistance to azoles, echinocandins, and polyenes complicating treatment. Early diagnosis using advanced molecular methods, such as MALDI-TOF MS and DNA sequencing, is crucial for effective management. Nursing interventions, including strict adherence to infection control protocols, patient monitoring, and education, are essential to prevent transmission and improve patient outcomes.C. auris represents a formidable challenge due to its multidrug resistance and ability to spread rapidly in healthcare settings. A multidisciplinary approach, including early diagnosis, targeted antifungal therapy, and robust infection control measures, is critical for managing C. auris infections. Nurses play a pivotal role in implementing these strategies to reduce transmission and improve patient care.

Keywords: *Candida Auris, Multidrug Resistance, Nosocomial Infections, Antifungal Resistance, Infection Control, Nursing Interventions, Molecular Diagnostics.*

[1] KSA, Ministry of Health, King Salman Hospital
[2] KSA, Ministry of Health, Prince Salman Bin Mohammed In Al Dilam.
[3] KSA, Ministry of Health, Aliman General Hospital.
[4] KSA, Ministry of Health, Al-Iman Genral Hospital.
[5] KSA, Ministry of Health, Al-Iman General Hospital
[6] KSA, Ministry of Health, King Khaled Hospital Alkharj
[7] KSA, Ministry of Health
[8] KSA, Ministry of Health, BIJADIYAH GENERAL HOSPITAL
[9] KSA, Ministry of Health, King Fahd Medical City
[10] KSA, Ministry of Health, Corporate Communication In The Madinah Health Cluster
[11] KSA, Ministry of Health, Madinah Health Cluster (Patient Experience)
[12] KSA, Ministry of Health, Al-Jouf Health Pool
[13] KSA, Ministry of Health, Second Health Cluster, King Khalid Hospital, Al Majmaah
[14] KSA, Ministry of Health, Primary Health Care Center In Artawiyah
[15] KSA, Ministry of Health, Artawiah PHC

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13255 – 13270
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6234

Introduction

Candida auris is an emerging pathogen causing nosocomial infections, posing a significant threat to global health. First identified in 2009 as a novel Candida species, C. auris has now been isolated in 35 countries, excluding Antarctica [1][2]. This pathogen has rapidly gained attention due to its ability to cause invasive infections associated with high mortality rates, particularly in immunocompromised patients or those with underlying health conditions. C. auris is notorious for its multi-drug resistance, showing varying resistance patterns to commonly used antifungal agents. This resistance complicates the treatment of infections, as traditional antifungal therapies are often ineffective against it. Over recent years, the increasing prevalence of infections caused by non-albicans Candida species, including C. auris, has been linked to the overuse of prophylactic antifungals, such as fluconazole. This widespread use has been attributed to contributing to the development of resistance in Candida species [3]. Laboratories often misidentify C. auris as other, more common yeasts, further complicating its detection and management. This misidentification occurs due to the limitations of traditional yeast identification methods, making the pathogen difficult to isolate and accurately diagnose. Transmission of C. auris primarily occurs in nosocomial settings, even in hospitals or healthcare facilities that implement infection prevention and control measures. The ability of C. auris to persist and spread in healthcare environments underscores the importance of vigilance in infection control practices. In the United States, C. auris is classified as a nationally notifiable pathogen,

Etiology

Candida auris is a yeast species within the genus *Candida*, first isolated from the external ear canal of a patient in a Japanese hospital, which led to its name [1]. Genomic DNA analysis revealed that *C. auris* is a distinct species, with a phylogenetic profile closely related to *Candida ruelliae*, *Candida haemulonii*, *C. duobushaemulonii*, and *C. pseudohaemulonii* [1][4]. *C. auris* is a budding yeast, with cells that can appear singly, in pairs, or in clusters. These cells are ovoid, ellipsoidal to elongate, and range from 2.5 to 5.0 micrometers in size. Unlike many other *Candida* species, *C. auris* rarely forms hyphae or pseudohyphae, nor does it produce germ tubes [5]. However, under certain stress conditions, such as high-salt environments (e.g., YTD media plus 10% NaCl) or depletion of heat-shock proteins (HSPs), pseudohyphae-like structures may develop [6][7]. *C. auris* is known to grow well at 40°C, but its growth rate slows significantly at 42°C [1]. The appearance of *C. auris* colonies on different culture media varies. On Sabouraud agar, the colonies are smooth and white to cream-colored [8]. On CHROMagar, colonies may show multiple color morphs, ranging from pale to dark pink, and occasionally beige. This variation in colonial appearance is one of the diagnostic features that can aid in identifying *C. auris* in laboratory settings.

Epidemiology

Candida auris is a globally emerging fungal pathogen that poses a significant threat to public health, particularly in healthcare settings. Genetic analysis of *C. auris* isolates has revealed four major geographical clades: South Asian, East Asian, South African, and South American, with a potential fifth clade traced to Iran [9]. These genetic differences suggest that *C. auris* may have emerged independently in these regions, possibly as a result of local factors influencing its adaptation and evolution. Despite its growing presence, the global prevalence of *C. auris* infections remains largely unknown, largely due to underreporting and limitations in diagnostic methods. Traditional yeast identification techniques often misidentify *C. auris* as other closely related *Candida* species, which complicates its detection and control [10]. The true scale of *C. auris* infections is difficult to ascertain, especially given the limitations of conventional diagnostic tools, and it is likely that many cases go undiagnosed.

Since its first identification in Japan in 2009, *C. auris* has spread rapidly worldwide, with confirmed cases across all continents except Antarctica. Early surveillance efforts, such as the international SENTRY Antifungal Surveillance Program, which reviewed 15,271 candidemia isolates collected between 2004 and 2015 from medical centers across Asia, Europe, Latin America, and North America, found no evidence of *C. auris* before 2009. This suggests that the organism was rare prior to that year [11]. Interestingly, retrospective studies of samples collected in South Korea (1996, 2004, and 2006) and Pakistan (2008)

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13255 – 13270
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6234

identified *C. auris* in misidentified isolates, indicating that the organism had likely emerged earlier than 2009 but was not recognized at the time [12]. The rapid global spread of *C. auris* began shortly after its initial description, with widespread cases reported by 2018. The pathogen has been detected in diverse regions, including the United States, Canada, Panama, Colombia, Venezuela, the United Kingdom, Germany, Switzerland, the Netherlands, France, Spain, Belgium, Norway, Russia, India, Pakistan, Bangladesh, Malaysia, China, Thailand, Singapore, Israel, Kuwait, Oman, the United Arab Emirates, Saudi Arabia, Iran, South Africa, Kenya, and Australia [13][14][15][16][17]. As of March 2020, the U.S. Centers for Disease Control and Prevention (CDC) reported *C. auris* isolates from 41 countries. Though *C. auris* is typically associated with nosocomial outbreaks, there have also been sporadic cases reported outside of these outbreaks, adding complexity to its epidemiology.

In the United States, the CDC recorded 1,092 confirmed cases of *C. auris* as of March 2020, with the majority of cases concentrated in New York City, New Jersey, and Illinois. Epidemiological data from these cases indicate that most of the strains were introduced from abroad, specifically from South America and South Asia [8]. While these strains belong to distinct clades originating in different parts of the world, the majority of the cases acquired the infection within U.S. healthcare settings. This points to clonal transmission of *C. auris* within hospitals and other healthcare facilities, underscoring its potential for nosocomial spread and highlighting the challenges of controlling its transmission in these environments [18][19]. The emergence and spread of *C. auris* have raised concerns about its impact on public health, especially in settings where patients are at heightened risk of fungal infections, such as intensive care units (ICUs) and other healthcare facilities that treat immunocompromised patients. The increasing prevalence of *C. auris* underscores the need for improved surveillance, early detection, and more effective infection control measures to limit its spread, especially in high-risk hospital settings. Additionally, as *C. auris* is often resistant to multiple classes of antifungal drugs, it presents a significant challenge for treatment and underscores the urgency of developing new therapeutic strategies and diagnostic tools.

Pathophysiology

Transmission

Candida auris is primarily transmitted through person-to-person contact, distinguishing it from many other *Candida* species, which are typically acquired from the host's own microflora. Unlike other *Candida* species, *C. auris* is not a resident organism of the human gastrointestinal tract and does not typically exist as part of the commensal flora [21]. Instead, *C. auris* has a strong preference for colonizing skin, especially areas such as the axilla and groin. It can colonize the host rapidly within days to weeks following exposure, and once colonized, invasive infections may develop within a similar time frame [22]. Furthermore, colonization with *C. auris* can persist for months, or even indefinitely, creating long-term reservoirs of infection and contributing to ongoing transmission within healthcare settings [23]. Asymptomatic colonization poses a significant risk in clinical environments, as these individuals can serve as sources for *C. auris* transmission to others, especially when they undergo medical procedures such as the placement of indwelling devices or surgical interventions. Thus, identifying asymptomatic carriers is crucial to prevent nosocomial outbreaks. *C. auris* is capable of spreading through contact with contaminated surfaces or fomites. It has been found on various surfaces within patient rooms, such as beds, chairs, counters, electrocardiogram leads, and ventilators, as well as in hallways and outside the patient's room [23]. Shared equipment like pulse oximeters, blood pressure cuffs, and temperature probes may act as vectors for transmission, serving as reservoirs for *C. auris* [24]. Studies show that *C. auris* can persist on both dry and moist surfaces for up to seven days, and in some cases, even longer. One study indicated that the yeast could remain viable for up to four weeks and cultivable for two weeks [25][26]. Therefore, strict isolation and contact precautions are essential to prevent its spread in healthcare settings.

Virulence Factors

The pathogenicity of *C. auris* can be attributed to several virulence factors that it shares with *Candida albicans*, including enzyme secretion, tissue invasion, nutrient acquisition, and the ability to form biofilms. Genetic studies have shown that a significant portion of the *C. auris* genome is involved in central metabolism, a

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13255 – 13270
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6234

characteristic feature of pathogenic *Candida* species that enables them to thrive in diverse environments [27]. *C. auris* produces a variety of virulence factors, including phospholipases, proteinases, and siderophores, all of which contribute to its ability to acquire nutrients, invade tissues, and evade host immune responses [28][29]. Virulence can vary by strain; a study of 16 *C. auris* isolates revealed differing levels of phospholipase and proteinase production, suggesting that these factors may be strain-dependent [30].

One of the most significant virulence attributes of *C. auris* is its ability to evade the host's immune system. Compared to *C. albicans*, *C. auris* is less susceptible to neutrophil-mediated killing. In fact, *C. auris* has been shown to evade neutrophil attacks and the innate immune response, a feature not observed in *C. albicans* [31]. Further studies have confirmed that *C. auris* has a reduced ability to stimulate the release of cytokines and promote phagocytosis, making it more challenging for the immune system to mount an effective defense against it [32]. Biofilm formation is another critical factor in *C. auris* pathogenicity. Like *C. albicans*, *C. auris* can form biofilms, which enhance its ability to adhere to surfaces and resist clearance by the host immune system or antifungal treatments. However, unlike *C. albicans*, *C. auris* forms biofilms less efficiently due to the rarity of pseudohyphae formation [30][33]. In vitro studies have shown that *C. auris* may exist in either an aggregating or non-aggregating form. Aggregating strains form large clusters of cells that are difficult to disrupt, even with detergent vortexing, which may aid in the yeast's survival in hospital environments. However, non-aggregating strains exhibit higher pathogenicity, suggesting that aggregation is not always linked to virulence [34]. Furthermore, *C. auris* demonstrates notable thermotolerance, with an optimal growth temperature of 37°C and the ability to survive at temperatures as high as 42°C. This thermotolerance aids in the persistence of *C. auris* in hospital environments, where temperatures can fluctuate but often remain within this range [30][34]. In conclusion, *Candida auris*' ability to colonize the skin, persist on surfaces, form biofilms, and evade the immune response contributes significantly to its virulence. These factors, combined with its resistance to multiple antifungal agents, make *C. auris* a formidable pathogen, especially in healthcare settings where it can spread rapidly and cause serious infections.

Resistance Factors

While *Candida auris* expresses virulence factors such as enzyme secretion, biofilm formation, and immune evasion, its most concerning feature is its ability to develop resistance to multiple antifungal agents. This resistance significantly contributes to its high mortality rates, as treatment options are often limited in cases of *C. auris* infection. One key mechanism by which *C. auris* demonstrates antifungal resistance is through biofilm formation. The biofilm matrix, which consists of a rich network of mannan-glucan polysaccharides, acts as a physical barrier that sequesters antifungal agents. This sequestration can reduce the effective concentration of the drug at the site of infection, leading to antifungal tolerance. A study highlighted that nearly 70% of the available triazole antifungal drug was sequestered within the extracellular matrix of the biofilm, rendering the antifungal less effective [36]. Biofilm-associated *C. auris* isolates are generally not susceptible to any antifungal class, including fluconazole, echinocandins, and polyenes, whereas planktonic *C. auris* isolates, in contrast, may only show resistance to fluconazole [37]. This difference further underscores the role of biofilms in protecting the organism from antifungal treatments.

Genetic studies have identified key mutations in *C. auris* that contribute to its resistance. One important genetic factor is the expansion of genes associated with drug resistance and multidrug efflux. Specifically, *C. auris* shows mutations in the *ERG11* gene, which encodes for lanosterol 14-alpha-demethylase, a target enzyme of azole antifungals. This mutation leads to a reduction in the efficacy of azoles, a commonly used class of antifungals [38]. Similarly, *C. auris* exhibits mutations in the *FSK1* gene, which encodes for 1,3-beta-glucan synthase, the target of echinocandin drugs. These mutations contribute to the resistance to echinocandins, another primary class of antifungal agents [38]. Efflux pumps also play a significant role in *C. auris*' resistance to azoles. The *C. auris* genome contains genes encoding for efflux pumps such as the ATP-binding cassette (ABC) transporters and the major facilitator superfamily (MFS) pumps. These efflux pumps actively expel antifungal agents from the cell, reducing their intracellular concentrations and thereby conferring resistance [29][39]. This mechanism is a common trait in multidrug-resistant organisms and represents a significant hurdle in the treatment of *C. auris* infections. In summary, *C. auris*' resistance to

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13255 – 13270
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6234

multiple antifungal classes is multifaceted. The ability to form biofilms, coupled with genetic mutations affecting drug target enzymes and the upregulation of efflux pumps, makes *C. auris* a particularly challenging pathogen to treat. Its resistance to azoles, echinocandins, and polyenes, along with its capacity for biofilm-associated tolerance, underscores the need for ongoing surveillance and the development of novel antifungal therapies.

History and Physical

The clinical presentation of *Candida auris* infection resembles that of other Candida species, although its behavior and transmission patterns are unique. *C. auris* has been isolated from a wide range of body sites, including both sterile and non-sterile sites. These include the nose, pharynx, sputum, lungs, pleural cavity, heart, blood, liver, abdominal cavity (peritoneal fluid), rectal or stool cultures, urine, vagina, bone, axilla, groin, wounds/surgical tissue, pus, ear, and brain [13][40]. While isolates from non-sterile body sites—such as the skin, genitourinary tract, and lungs—are typically indicative of colonization rather than active infection, they may still serve as sources for further transmission, particularly in hospital settings [8]. Colonization can occur within hours to days of exposure and may lead to invasive infections, which may take days to months to develop after the initial colonization. *C. auris*' ability to colonize skin, particularly in moist areas like the axilla and groin, is a distinguishing feature compared to other Candida species, which are typically commensals of the gastrointestinal tract and not associated with nosocomial transmission [22].

Clinical conditions associated with *C. auris* infections include bloodstream infections (fungemia), myocarditis, urinary tract infections, surgical wound infections, burn infections, skin abscesses (often related to catheter insertion), otitis, meningitis, and bone infections [1][12][41][42][5][43][44][45]. The presence of indwelling medical devices, such as venous catheters, ports, urinary catheters, and prosthetic devices, significantly increases the risk of infection. These devices should be closely monitored for signs of erythema, tenderness, and purulent material. The biofilm-forming nature of *C. auris* enhances its ability to adhere to surfaces, including both human skin and medical devices. This multilayer biofilm proliferates best in environments resembling the conditions found in sweaty axillary skin [46]. Biofilm formation is another key factor that contributes to the persistence of colonization and infection in healthcare settings, making it particularly difficult to eradicate from hospital environments. Colonized patients act as reservoirs and sources of transmission to other vulnerable patients, further compounding the difficulty in controlling outbreaks in nosocomial environments. In summary, the clinical features of *C. auris* infections span a wide range of body systems, and its transmission is strongly associated with colonization, particularly on the skin and in patients with indwelling devices. Due to its unique transmission patterns and ability to form biofilms, strict infection control practices are critical in preventing the spread of *C. auris* in healthcare settings.

Risk Factors for Candida auris Infections

The risk factors for *Candida auris* infections are largely consistent with those seen in other Candida species. These factors primarily involve conditions that compromise the immune system or provide a route for the organism to enter the body. Key risk factors include:

- Presence of a central venous catheter: The use of central venous catheters creates a direct pathway for *C. auris* to enter the bloodstream, making patients more susceptible to bloodstream infections (fungemia).

- Indwelling urinary catheter: Similar to central venous catheters, urinary catheters provide a route for *C. auris* to invade the urinary tract, leading to infections such as candiduria or urinary tract infections (UTIs).

- Immunosuppressive states: Conditions such as human immunodeficiency virus (HIV), hematologic malignancies, solid tumors, transplant recipients, neutropenia, chemotherapy, and corticosteroid therapy significantly increase the risk of infection by weakening the body's natural defenses against pathogens.

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13255 – 13270
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6234

- Diabetes mellitus: Uncontrolled diabetes can impair immune function and increase the susceptibility to fungal infections, including those caused by *C. auris*.

- Chronic kidney disease: Patients with chronic kidney disease, particularly those on dialysis, are at heightened risk for *C. auris* infections, possibly due to altered immune responses and increased use of medical devices.

- Exposure to broad-spectrum antibiotics or previous exposure to antifungal agents: The use of broad-spectrum antibiotics disrupts normal microbiota and allows *C. auris* to colonize and infect the host. Prior antifungal therapy can also contribute to resistance development in *C. auris*.

- Concomitant bacteremia or candiduria: The presence of concurrent bacterial infections or candiduria increases the risk of *C. auris* infection, especially in critically ill patients.

- Parenteral nutrition: The use of parenteral nutrition can increase the risk of infection, particularly in patients with central venous catheters, as it may create an ideal medium for fungal growth.

- Blood transfusion: Receiving blood products, particularly in immunocompromised patients, increases the risk of *C. auris* infection, as it can be a source of transmission.

- Hemodialysis: Patients undergoing hemodialysis are more vulnerable to infections, including *C. auris*, due to frequent exposure to medical devices and compromised immune function.

- Surgery within 30 days: Recent surgery can predispose patients to infection by providing an entry point for *C. auris* and other pathogens.

- Admission to intensive care units (ICUs): ICU patients, particularly those with prolonged stays, are at increased risk due to the use of invasive devices, exposure to antibiotics, and the highly transmissible nature of *C. auris* in these settings.

These risk factors highlight the vulnerability of critically ill or immunocompromised patients, particularly those in healthcare settings where *C. auris* transmission can be facilitated by invasive procedures and prolonged exposure to antibiotics. Identification and management of these risk factors are essential for preventing *C. auris* infections in at-risk populations.

Evaluation of Candida auris Infection

The evaluation of a suspected *Candida auris* infection begins with obtaining clinical specimens from the site of infection. These specimens may include blood, urine, nasal or throat swabs, sputum, pleural cavity fluid, heart, bile, peritoneal fluid, stool, vaginal swabs, bone, axilla, groin, wounds, surgical tissue, pus, ear, or cerebrospinal fluid. Once collected, the specimens are sent for culture, staining, and/or histopathological examination. It is essential to differentiate between a true infection and colonization, especially when cultures are obtained from non-sterile sites, as these may represent colonization rather than an active infection. Blood cultures, in particular, typically take 1 to 3 days for growth and an additional 1 to 2 days for identification after subculture onto agar medium.

Challenges in Identification

Accurate identification of *Candida auris* is notoriously difficult, as it is commonly misidentified by standard clinical microbiology methods. Phenotypic characteristics, such as colony appearance on culture media, may offer some clues but are not sufficient for definitive diagnosis. Many biochemical methods, including automated testing systems, often misidentify *C. auris* as other Candida species, such as *Candida haemulonii* or other similar yeasts [47].

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13255 – 13270
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6234

Molecular Methods for Accurate Identification

- MALDI-TOF MS (Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry) MALDI-TOF MS is the most accurate method for identifying *Candida auris*. This technology relies on spectral analysis of microbial samples to differentiate *C. auris* from other Candida species. However, it is important to note that the initial MALDI-TOF MS databases were prone to misidentifying *C. auris* as *C. albicans* or *C. haemulonii*. Once additional spectra for *C. auris* strains are incorporated into the database, the identification becomes more accurate, although it still depends on the comprehensiveness of the spectral library, particularly for distinguishing between different geographical strains of *C. auris* [48][49].

- Molecular Sequencing: The sequencing of the D1-D2 region of the 28S rDNA or the internal transcribed spacer (ITS) region of rDNA has also been employed for accurate molecular identification of *C. auris*. These molecular techniques provide reliable species-level identification and can overcome the limitations of phenotypic methods [10][51].

- Automated Molecular Testing: Another promising method is the automated molecular test based on competitive DNA hybridization and electrochemical detection. This test can rapidly detect *C. auris* among 15 different fungal pathogens. A multi-center study demonstrated that this test has 100% sensitivity and specificity for *C. auris* and other Candida species like *C. dubliniensis*, *C. famata*, and *C. krusei*. This method can also distinguish other common Candida species, including *C. albicans*, *C. glabrata*, *C. lusitaniae*, *C. tropicalis*, and *C. parapsilosis*. However, the availability of such advanced molecular tests may be limited in certain healthcare settings, making the diagnosis and management of *C. auris* infections more challenging [52].

- Amplified Fragment Length Polymorphism (AFLP): AFLP analysis has been used for typing *C. auris* isolates and has shown utility in identifying geographical clusters of this pathogen. AFLP can be a helpful tool in epidemiological studies, as it allows for the tracking of the spread of *C. auris* and helps to map its distribution globally [53].

Due to its ability to colonize various body sites and its potential for misidentification by traditional methods, diagnosing *Candida auris* requires advanced laboratory techniques. The most accurate methods involve molecular approaches such as MALDI-TOF MS, DNA sequencing, and competitive DNA hybridization tests. Despite these advancements, the availability of such diagnostic tools can vary across healthcare facilities, which complicates the timely and accurate identification of *C. auris*. Therefore, awareness of the challenges in diagnosis and the need for advanced molecular methods is crucial for effective management and infection control efforts.

Treatment and Management of Candida auris Infections

The management of invasive *Candida auris* infections is complicated by its significant drug resistance. *C. auris* can develop resistance to the three primary classes of antifungals, azoles, polyenes, and echinocandins, making treatment challenging. A study from India found that 90% of *C. auris* isolates were resistant to azoles (e.g., fluconazole), 8% were resistant to polyenes (e.g., amphotericin B), and 2% to echinocandins (e.g., anidulafungin, micafungin) [38]. Additionally, 25% of isolates were multidrug-resistant, and 13% were resistant to multiple azoles [38]. In the U.S., the Centers for Disease Control and Prevention (CDC) found exceptionally high minimum inhibitory concentrations (MIC) for azoles, echinocandins, polyenes, and nucleoside analogs in *C. auris* isolates [54]. In vitro studies have suggested that combination with antifungal therapy might offer some benefit. For example, a combination of voriconazole and micafungin has shown promising results against multidrug-resistant isolates [55]. However, other combinations of echinocandins and azoles have not been effective. Despite these findings, no definitive therapeutic regimen for *C. auris* has been established, and most cases are managed on an individualized basis using susceptibility testing.

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13255 – 13270
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6234

For treatment, it is crucial to start therapy only in the presence of clinical disease, particularly in patients who are colonized with *C. auris* but are not infected. Colonization, particularly from non-invasive sites (e.g., skin, respiratory tract, or urine), does not typically require treatment [13]. The CDC recommends starting empirical therapy with echinocandins, such as caspofungin or micafungin, for adults and children older than two months of age. For infants under two months, amphotericin B deoxycholate is preferred initially, followed by liposomal amphotericin B [56][57]. Monitoring for clinical improvement and repeat blood cultures are essential to ensure the clearance of fungemia. Resistance to echinocandins may develop, so susceptibility testing should be repeated, and therapy may need adjustment. In cases where patients are unresponsive to echinocandin therapy, liposomal amphotericin B may be considered [56]. If central nervous system (CNS) involvement is suspected, echinocandins should be used cautiously, and amphotericin B combined with 5-flucytosine is recommended for CNS involvement and urinary tract infections [59][60]. Apart from antifungal therapy, the management of *C. auris* infections involves the removal of central venous catheters or other indwelling devices and draining abscesses or other collections of infected material as soon as possible. In cases of persistent positive blood cultures, a search for metastatic infection is necessary, including evaluating for endocarditis, suppurative thrombophlebitis, or abscess formation. The Infectious Disease Society of America recommends continuing antifungal therapy for at least two weeks after blood cultures become negative in patients without obvious metastatic complications [58]. Additionally, for non-neutropenic patients with candidemia, a dilated ophthalmologic exam should be performed to check for endophthalmitis or other ocular complications.

Preventing invasive infections in colonized individuals involves reducing the risk of introducing *C. auris* to sterile body sites. This includes careful use and prompt removal of invasive devices such as central venous catheters and urinary catheters. Surgical patients should undergo thorough skin preparation with an alcohol-based antiseptic to minimize the risk of contamination [13]. The site of infection plays a critical role in the choice of antifungal treatment. Echinocandins, due to their large molecular size, have limited penetration into certain areas such as the cerebrospinal fluid, making them less effective for central nervous system infections [59]. For urinary tract infections, amphotericin B with 5-flucytosine may be used. Similarly, in CNS infections, a combination of amphotericin B and 5-flucytosine has shown some success, with therapy tailored based on susceptibility testing [60]. In summary, the management of *C. auris* infections requires a multifaceted approach, including timely antifungal therapy, the removal of infected medical devices, and careful monitoring for resistance. Empirical treatment with echinocandins is commonly recommended, but the choice of antifungal should be tailored to the site of infection and the results of susceptibility testing. Preventive measures, including the careful use of medical devices and diligent infection control practices, are essential to mitigate the spread of *C. auris*.

Differential Diagnosis

The differential diagnosis of *Candida auris* infection primarily involves distinguishing it from other invasive fungal infections caused by *Candida* species, which account for 95% of all such infections [2]. The most common *Candida* species include *Candida albicans*, *Candida glabrata*, *Candida tropicalis*, *Candida paratropicalis*, and *Pichia kudriavzevii*. In addition to other *Candida* species, other potential pathogens to consider include Aspergillosis, bacterial sepsis, cryptococcosis, and septic shock. Although *C. auris* infections are more frequent in immunocompromised individuals, it can also affect immunocompetent hosts. Therefore, clinical presentation alone is insufficient for distinguishing *C. auris* from other *Candida* species, as their symptoms may overlap. Phenotypic characteristics, such as colony appearance, color, heat tolerance (up to 42°C), and the ability to thrive in saline environments, may provide some clues. However, these phenotypic methods should not be relied upon solely, as they often misidentify *C. auris* as species like *C. haemulonii*, *C. famata*, *C. guilliermondii*, *C. lusitaniae*, and others. Molecular identification techniques, such as DNA sequencing, remain the gold standard for accurate and definitive diagnosis of *C. auris* infections.

Prognosis

The prognosis for invasive *Candida auris* infections is generally worse than that for other *Candida* species, with crude mortality rates ranging from 30% to 72% [11][62][63][64]. These figures can vary significantly based on several factors, including the extent of the infection, the patient's age, and the presence of co-

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13255 – 13270
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6234

morbid conditions. Older adults, immunocompromised individuals, and those with chronic diseases, such as diabetes and kidney failure, are more likely to experience poor outcomes. Conversely, pediatric populations, particularly neonates and infants, have shown relatively higher survival rates [65]. This variation in outcomes may also be influenced by factors like the type of antifungal therapy used and the timeliness of intervention. Early identification of *C. auris* infections is critical for improving patient survival, as it allows for the initiation of targeted antifungal therapy. Prompt initiation of appropriate antifungal treatment, guided by susceptibility testing, is associated with higher survival rates and a better overall prognosis [12]. The emergence of antifungal resistance, particularly to azoles, has made the treatment of *C. auris* more challenging, which may contribute to the high mortality observed. It is crucial for clinicians to initiate empirical treatment promptly while awaiting culture and sensitivity results. Surveillance and early detection of *C. auris* colonization in at-risk patients can also play a crucial role in reducing the impact of the infection.

Complications

Invasive *Candida auris* infections can lead to a wide range of complications, depending on the infection's severity and the patient's overall health. Fungemia, or bloodstream infection, is the most common presentation of *C. auris* infection and can lead to hematogenous spread, seeding different organs and causing multi-organ dysfunction. If the infection is not controlled, it can escalate quickly, leading to septic shock, organ failure, and death. Organs commonly affected include the kidneys, lungs, liver, heart, and brain, each of which can contribute to severe morbidity. When *C. auris* infection is localized initially, it may progress to bloodstream infections, particularly in patients with central venous catheters or other invasive medical devices. Sepsis, a systemic inflammatory response to infection, is a major complication and can lead to multi-organ failure, including renal and cardiac dysfunction. Neurological complications, such as meningitis or cerebral abscesses, have also been reported in patients with *C. auris* infections, particularly in those with compromised immune systems or invasive devices [40][62]. Eye complications, such as chorioretinitis or endophthalmitis, are also common in immunocompromised individuals and may lead to permanent vision loss. Because *C. auris* infections are often associated with high levels of antifungal resistance, patients may experience prolonged infections despite aggressive treatment, resulting in higher risk for complications. Multi-organ involvement and septic shock may lead to long-term disabilities or death, especially in critically ill or immunocompromised patients. The high mortality and complexity of managing *C. auris* infections underscore the need for prompt diagnosis and comprehensive, multi-disciplinary care.

Patient Education

Given the high rates of transmissibility and antifungal resistance, *Candida auris* (C. auris) has become a significant public health threat. In response to its emergence, the Centers for Disease Control and Prevention (CDC) declared it a public health concern in 2016. The CDC's announcement required that all cases of *C. auris* in the United States be reported to public health authorities, providing a framework for enhanced surveillance and control measures [8]. Since then, the CDC has outlined detailed infection control and prevention strategies to curb the spread of this multidrug-resistant pathogen. Educating patients and healthcare providers on these strategies is essential to reducing its impact. Hand hygiene is the cornerstone of infection control for *C. auris*. Healthcare personnel should adhere to standard hand hygiene protocols to minimize the organism's transmission. Alcohol-based hand rubs are recommended, as they are effective against *C. auris*, and chlorhexidine hand rubs should be used when hands are not visibly soiled. In cases where hands are visibly dirty, soap and water should be used to clean hands thoroughly [66]. Furthermore, gloves and gowns must be worn as part of contact precautions, emphasizing that gloves should not replace hand hygiene. These basic infection control practices help prevent the spread of *C. auris* in healthcare settings, particularly in environments with high-risk populations.

Infection control strategies for *C. auris* are similar to those used for other multidrug-resistant organisms like *Clostridium difficile*. Given the organism's propensity for swift nosocomial spread, infection control measures are applied not only to patients with active infections but also to those who are colonized, as they can still transmit the pathogen. The CDC recommends transmission-based precautions in both acute care hospitals

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13255 – 13270
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6234

and long-term care facilities, such as skilled nursing homes, particularly those with ventilator units. Contact precautions are mandatory in acute care settings, while skilled nursing facilities may adopt either contact precautions or enhanced barrier precautions to prevent further transmission [18]. Patients with *C. auris* should ideally be placed in single rooms to limit exposure to other patients. If single-room placement is not feasible, they should be placed in cohort settings with only other *C. auris*-infected or colonized individuals, ensuring that they are isolated from patients with other multidrug-resistant organisms. This is vital to prevent cross-contamination between different resistant pathogens. Even after the acute infection is treated, patients may remain colonized with *C. auris* for prolonged periods, sometimes up to months. Therefore, contact precautions should be continued during their hospitalization. Although routine colonization screening is not recommended by the CDC, patients who have been hospitalized for extended periods or those residing in nursing homes may undergo screening three months after their last positive test, provided they have not received antifungal therapy for at least one week or topical antiseptic for 48 hours. Contact precautions can be discontinued if two consecutive negative colonization tests are obtained at least one week apart.

Environmental disinfection is another critical component of infection control, as *C. auris* can persist on various surfaces within healthcare environments. Routine cleaning and disinfection of the patient's room and all shared equipment should be performed daily. Not all fungicidal products are effective against *C. auris*, and common quaternary ammonia compounds may not suffice. For optimal disinfection, the CDC recommends using specific agents such as sodium hypochlorite and hydrogen peroxide, which have been shown to be effective against *C. auris* [67][69]. In vitro studies support the use of these agents, and environmental studies have demonstrated that sodium hypochlorite and hydrogen peroxide vapor are effective at cleaning rooms contaminated with *C. auris* [18][70]. Ultraviolet light, while commonly employed in environmental disinfection, has proven ineffective against this pathogen [68]. The importance of proper environmental disinfection cannot be overstated, as inadequate cleaning of shared spaces and equipment can lead to persistent contamination and increase the risk of patient-to-patient transmission. Patient education plays a critical role in preventing *C. auris* outbreaks and ensuring effective control measures. Healthcare providers should educate patients and their families about the importance of hand hygiene, contact precautions, and the need for continuous environmental cleaning. Ensuring that patients understand why these measures are necessary will help them adhere to infection control practices during their hospital stays. Additionally, educating patients on the potential for prolonged colonization and the importance of regular screenings can help minimize the risk of *C. auris* transmission once they leave the healthcare setting. Given the challenges posed by this multidrug-resistant organism, a comprehensive approach to patient education, infection control, and environmental management is crucial for preventing the spread of *C. auris* in healthcare settings.

Enhancing Healthcare Team Outcomes

Candida auris is an emerging fungal pathogen linked to nosocomial infections, posing a serious global health threat. Effective management of *C. auris* infections requires a collaborative approach from an interprofessional healthcare team, which should include epidemiologists, clinicians, nurses, medical technicians, pharmacists, and laboratory personnel. These professionals are essential in monitoring the pathogen's spread, ensuring accurate diagnosis, and implementing appropriate infection control measures. *C. auris* exhibits multidrug resistance to commonly used antifungal therapies, complicating its treatment and making early identification and intervention crucial for improving patient outcomes. Interprofessional communication is vital at all stages of patient care. Clear and consistent communication between all healthcare providers, including nurses, pharmacists, laboratory technicians, clinicians, and specialists, is necessary for effective case management. Each team member should be well-informed about the severity of *C. auris* and its potential to cause outbreaks. Open communication not only helps in delivering optimal care to the individual patient but also plays a critical role in preventing or containing outbreaks within the broader community. Regularly sharing up-to-date information about patient status, infection control measures, and treatment protocols is essential for managing the infection and preventing further transmission. This team coordination and timely information sharing significantly enhance healthcare outcomes [Level 5].

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13255 – 13270
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6234

Education and training are critical to enhancing the team's effectiveness in controlling *C. auris* infections. Staff members must be knowledgeable about best practices for disinfecting patient rooms and environmental surfaces to reduce the risk of transmission. Specialized training on handling *C. auris* specimens and interpreting microbiological data should be provided to laboratory technicians to ensure accurate and rapid identification of the pathogen. In cases of suspected or confirmed *C. auris* infection, infectious disease specialists should collaborate with microbiology technicians to obtain antibiogram information and tailor treatment options effectively. Additionally, consultations with specialized pharmacists can help ensure the appropriate selection and administration of antifungal therapies. In healthcare settings, *C. auris* infections often occur in clusters, which poses a significant risk of widespread outbreaks, especially in high-risk environments such as intensive care units. Therefore, it is essential to have a clear protocol in place for infection prevention and control. The infection prevention and control officer within the healthcare facility should be promptly notified when a *C. auris* case is identified. This individual is responsible for guiding staff on appropriate infection control measures, including isolation precautions and environmental cleaning. In the event of an outbreak, the officer coordinates the efforts of the interprofessional team to contain the spread of the pathogen. Furthermore, as *C. auris* is a reportable pathogen, it is essential that healthcare providers notify the Centers for Disease Control and Prevention (CDC) of all cases. This allows for enhanced surveillance and helps public health authorities track the spread of the infection. By sharing data and collaborating with global health bodies, healthcare teams can contribute to larger efforts to combat the pathogen and prevent further outbreaks. In conclusion, a coordinated, interprofessional approach is crucial for improving healthcare team outcomes in the management of *C. auris* infections.

Nursing Interventions and Management Protocols

The nursing management of *Candida auris* infections is critical for minimizing the risk of transmission and improving patient outcomes, especially in healthcare settings where this pathogen is most prevalent. Nurses play a key role in the early detection, treatment, and prevention of *C. auris* infections, contributing to both individual patient care and broader infection control efforts. Since *C. auris* is multidrug-resistant and difficult to diagnose, a multifaceted approach is essential for its management, involving surveillance, prompt treatment, and strict adherence to infection control protocols. Early recognition of potential *C. auris* infections is the first step in nursing interventions. Nurses should be vigilant for signs and symptoms of bloodstream infections (fungemia) and other systemic manifestations, particularly in patients with risk factors such as immunosuppression, prolonged hospital stays, and the use of invasive medical devices. *C. auris* often presents with nonspecific symptoms, making clinical suspicion and prompt microbiological testing essential. Nurses are responsible for notifying healthcare providers about any changes in the patient's condition that may indicate an infection, especially in critically ill or immunocompromised patients. In collaboration with other healthcare professionals, nurses should ensure that appropriate diagnostic samples are collected for culture and susceptibility testing to confirm the presence of *C. auris* and guide treatment. The primary focus of nursing interventions is the prevention of *C. auris* transmission. As a highly contagious pathogen, *C. auris* can spread rapidly within healthcare settings, necessitating strict adherence to infection control measures. Nurses must ensure the implementation of standard and transmission-based precautions, including the use of personal protective equipment (PPE) such as gloves, gowns, and masks. Isolation precautions, including the placement of affected patients in single rooms or in cohorts with others infected with *C. auris*, are vital to minimize cross-contamination. Nurses must educate patients, families, and other healthcare staff on the importance of these measures. In addition, nursing staff should strictly follow hand hygiene protocols, using alcohol-based hand rubs or chlorhexidine, and ensuring that hand hygiene is performed before and after patient contact, even when gloves are worn.

Another important nursing responsibility is the continuous monitoring of patients for clinical changes that may indicate worsening infection or complications. This includes regular vital sign assessments, tracking fever, and performing laboratory tests to assess for markers of systemic infection, such as elevated white blood cell counts. Nurses should be proactive in monitoring the effectiveness of antifungal treatments, ensuring that prescribed regimens are followed and that adverse reactions are detected early. If the patient's condition does not improve or deteriorates, nursing staff must immediately report findings to the medical

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13255 – 13270
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6234

team for potential adjustments in therapy. In managing *C. auris* infections, nurses must collaborate closely with infectious disease specialists, microbiology technicians, and pharmacists. The role of the nurse in supporting antimicrobial stewardship is critical, as the use of inappropriate antifungals can exacerbate resistance. For patients diagnosed with *C. auris* infections, nurses should assist in administering the prescribed antifungal therapies, such as echinocandins or, in some cases, liposomal amphotericin B. Monitoring for side effects and effectiveness is essential, especially given the risk of antifungal resistance. Nurses should also facilitate follow-up diagnostic testing, including repeat blood cultures, to assess treatment response and ensure the clearance of the infection. Environmental cleaning is another critical nursing intervention in managing *C. auris*. Nurses should work with infection control teams to ensure that patient rooms and shared equipment are properly disinfected. This includes the use of effective cleaning agents, such as sodium hypochlorite or hydrogen peroxide, which have been shown to be effective against *C. auris*. Nurses should ensure that all healthcare workers follow these cleaning protocols, as environmental contamination is a significant route of transmission. Additionally, they must educate patients and family members about the importance of environmental hygiene, particularly in settings like long-term care facilities where *C. auris* is commonly found.

Nurses should also advocate for timely and effective communication across the healthcare team. They need to ensure that relevant information, such as the patient's infection status, susceptibility test results, and any changes in clinical condition, is communicated promptly to all team members, including physicians, laboratory technicians, and pharmacists. This collaboration ensures that the patient receives the most effective treatment and care. Nurses should also maintain detailed records, including infection control practices, medication administration, and patient assessments, to monitor progress and ensure accountability. Finally, patient and family education is a crucial aspect of nursing care. Nurses should educate patients and families about the nature of *C. auris* infections, the importance of adherence to infection control measures, and the need for follow-up care. For patients who may be colonized with *C. auris*, even if they are not currently infected, nurses should explain the importance of maintaining precautions to prevent transmission. Ensuring that the patient and family understand the need for strict adherence to infection control protocols is essential for preventing the spread of *C. auris* both within healthcare facilities and in the community. In conclusion, nursing interventions in the management of *Candida auris* infections are multifaceted, requiring vigilance, adherence to infection control measures, ongoing patient monitoring, and effective communication across the healthcare team. Nurses play a pivotal role in preventing the spread of *C. auris*, ensuring appropriate treatment, and educating patients and staff about best practices. Through these efforts, nurses contribute to improving patient outcomes and minimizing the impact of this emerging fungal pathogen.

Conclusion

Candida auris (C. auris) has emerged as a significant global health threat, particularly in healthcare settings, due to its multidrug resistance, high mortality rates, and ability to persist in the environment. Since its first identification in 2009, C. auris has spread rapidly across the globe, with cases reported in over 35 countries. Its resistance to commonly used antifungal agents, including azoles, echinocandins, and polyenes, complicates treatment and underscores the urgent need for novel therapeutic strategies. Additionally, the pathogen's ability to colonize patients asymptomatically and persist on surfaces for extended periods facilitates its transmission in healthcare environments, making infection control a critical component of its management. The challenges posed by C. auris are multifaceted. Traditional diagnostic methods often misidentify the pathogen, delaying appropriate treatment and facilitating its spread. Advanced molecular techniques, such as MALDI-TOF MS and DNA sequencing, are essential for accurate identification. However, the availability of these tools varies across healthcare settings, highlighting the need for increased investment in diagnostic infrastructure. Treatment of C. auris infections is further complicated by its resistance to multiple antifungal classes, necessitating individualized therapy based on susceptibility testing. Empirical treatment with echinocandins is recommended, but resistance development remains a concern, emphasizing the importance of ongoing surveillance and research into new antifungal agents. Infection control measures are paramount in preventing the spread of C. auris. Strict adherence to hand hygiene, environmental disinfection, and patient isolation protocols can significantly reduce transmission rates.

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13255 – 13270
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6234

Nurses play a critical role in implementing these measures, monitoring patients for signs of infection, and educating both patients and healthcare staff about the importance of infection prevention. Environmental cleaning with effective agents, such as sodium hypochlorite and hydrogen peroxide, is essential to eliminate C. auris from healthcare settings. In conclusion, the emergence of C. auris as a multidrug-resistant pathogen requires a coordinated, multidisciplinary approach to management. Early diagnosis, targeted antifungal therapy, and robust infection control measures are essential to mitigate its impact. Nurses, as frontline healthcare providers, are integral to these efforts, ensuring that infection control protocols are followed, and patients receive optimal care. By addressing the challenges posed by C. auris through collaboration and innovation, healthcare systems can better protect vulnerable populations and reduce the global burden of this formidable pathogen.

References

Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009 Jan;53(1):41-4.

Sabino R, Veríssimo C, Pereira ÁA, Antunes F. Candida auris, an Agent of Hospital-Associated Outbreaks: Which Challenging Issues Do We Need to Have in Mind? Microorganisms. 2020 Jan 28;8(2)

Deorukhkar SC, Saini S, Mathew S. Non-albicans Candida Infection: An Emerging Threat. Interdiscip Perspect Infect Dis. 2014;2014:615958.

Muñoz JF, Gade L, Chow NA, Loparev VN, Juieng P, Berkow EL, Farrer RA, Litvintseva AP, Cuomo CA. Genomic insights into multidrug-resistance, mating and virulence in Candida auris and related emerging species. Nat Commun. 2018 Dec 17;9(1):5346.

Chowdhary A, Sharma C, Duggal S, Agarwal K, Prakash A, Singh PK, Jain S, Kathuria S, Randhawa HS, Hagen F, Meis JF. New clonal strain of Candida auris, Delhi, India. Emerg Infect Dis. 2013 Oct;19(10):1670-3.

Wang X, Bing J, Zheng Q, Zhang F, Liu J, Yue H, Tao L, Du H, Wang Y, Wang H, Huang G. The first isolate of Candida auris in China: clinical and biological aspects. Emerg Microbes Infect. 2018 May 18;7(1):93.

Kim SH, Iyer KR, Pardeshi L, Muñoz JF, Robbins N, Cuomo CA, Wong KH, Cowen LE. Genetic Analysis of Candida auris Implicates Hsp90 in Morphogenesis and Azole Tolerance and Cdr1 in Azole Resistance. mBio. 2019 Jan 29;10(1)

Cortegiani A, Misseri G, Fasciana T, Giammanco A, Giarratano A, Chowdhary A. Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris. J Intensive Care. 2018;6:69.

Chow NA, de Groot T, Badali H, Abastabar M, Chiller TM, Meis JF. Potential Fifth Clade of Candida auris, Iran, 2018. Emerg Infect Dis. 2019 Sep;25(9):1780-1781.

Kordalewska M, Zhao Y, Lockhart SR, Chowdhary A, Berrio I, Perlin DS. Rapid and Accurate Molecular Identification of the Emerging Multidrug-Resistant Pathogen Candida auris. J Clin Microbiol. 2017 Aug;55(8):2445-2452.

Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP, Colombo AL, Calvo B, Cuomo CA, Desjardins CA, Berkow EL, Castanheira M, Magobo RE, Jabeen K, Asghar RJ, Meis JF, Jackson B, Chiller T, Litvintseva AP. Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses. Clin Infect Dis. 2017 Jan 15;64(2):134-140.

Lee WG, Shin JH, Uh Y, Kang MG, Kim SH, Park KH, Jang HC. First three reported cases of nosocomial fungemia caused by Candida auris. J Clin Microbiol. 2011 Sep;49(9):3139-42.

Lone SA, Ahmad A. Candida auris-the growing menace to global health. Mycoses. 2019 Aug;62(8):620-637.

Ben-Ami R, Berman J, Novikov A, Bash E, Shachor-Meyouhas Y, Zakin S, Maor Y, Tarabia J, Schechner V, Adler A, Finn T. Multidrug-Resistant Candida haemulonii and C. auris, Tel Aviv, Israel. Emerg Infect Dis. 2017 Feb;23(1):195-203.

Ruiz Gaitán AC, Moret A, López Hontangas JL, Molina JM, Aleixandre López AI, Cabezas AH, Mollar Maseres J, Arcas RC, Gómez Ruiz MD, Chiveli MÁ, Cantón E, Pemán J. Nosocomial fungemia by Candida auris: First four reported cases in continental Europe. Rev Iberoam Micol. 2017 Jan-Mar;34(1):23-27.

Al-Siyabi T, Al Busaidi I, Balkhair A, Al-Muharrmi Z, Al-Salti M, Al'Adawi B. First report of Candida auris in Oman: Clinical and microbiological description of five candidemia cases. J Infect. 2017 Oct;75(4):373-376.

Schwartz IS, Hammond GW. First reported case of multidrug-resistant Candida auris in Canada. Can Commun Dis Rep. 2017 Jul 06;43(7-8):150-153.

Tsay S, Welsh RM, Adams EH, Chow NA, Gade L, Berkow EL, Poirot E, Lutterloh E, Quinn M, Chaturvedi S, Kerins J, Black SR, Kemble SK, Barrett PM, MSD. Barton K, Shannon DJ, Bradley K, Lockhart SR, Litvintseva AP, Moulton-Meissner H, Shugart A, Kallen A, Vallabhaneni S, Chiller TM, Jackson BR. Notes from the Field: Ongoing Transmission of Candida auris in Health Care Facilities - United States, June 2016-May 2017. MMWR Morb Mortal Wkly Rep. 2017 May 19;66(19):514-515.

Vallabhaneni S, Kallen A, Tsay S, Chow N, Welsh R, Kerins J, Kemble SK, Pacilli M, Black SR, Landon E, Ridgway J, Palmore TN, Zelzany A, Adams EH, Quinn M, Chaturvedi S, Greenko J, Fernandez R, Southwick K, Furuya EY, Calfee DP, Hamula C, Patel G, Barrett P, Lafaro P, Berkow EL, Moulton-Meissner H, Noble-Wang J, Fagan RP, Jackson BR, Lockhart SR, Litvintseva AP, Chiller TM. Investigation of the First Seven Reported Cases of Candida auris, a Globally Emerging Invasive, Multidrug-Resistant Fungus-United States, May 2013-August 2016. Am J Transplant. 2017 Jan;17(1):296-299.

Spivak ES, Hanson KE. Candida auris: an Emerging Fungal Pathogen. J Clin Microbiol. 2018 Feb;56(2)

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13255 – 13270
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6234
Day AM, McNiff MM, da Silva Dantas A, Gow NAR, Quinn J. Hog1 Regulates Stress Tolerance and Virulence in the Emerging Fungal Pathogen Candida auris. mSphere. 2018 Oct 24;3(5)
Forsberg K, Woodworth K, Walters M, Berkow EL, Jackson B, Chiller T, Vallabhaneni S. Candida auris: The recent emergence of a multidrug-resistant fungal pathogen. Med Mycol. 2019 Jan 01;57(1):1-12.
Biswal M, Rudramurthy SM, Jain N, Shamanth AS, Sharma D, Jain K, Yaddanapudi LN, Chakrabarti A. Controlling a possible outbreak of Candida auris infection: lessons learnt from multiple interventions. J Hosp Infect. 2017 Dec;97(4):363-370.
Cortegiani A, Misseri G, Giarratano A, Bassetti M, Eyre D. The global challenge of Candida auris in the intensive care unit. Crit Care. 2019 May 02;23(1):150.
Piedrahita CT, Cadnum JL, Jencson AL, Shaikh AA, Ghannoum MA, Donskey CJ. Environmental Surfaces in Healthcare Facilities are a Potential Source for Transmission of Candida auris and Other Candida Species. Infect Control Hosp Epidemiol. 2017 Sep;38(9):1107-1109.
Welsh RM, Bentz ML, Shams A, Houston H, Lyons A, Rose LJ, Litvintseva AP. Survival, Persistence, and Isolation of the Emerging Multidrug-Resistant Pathogenic Yeast Candida auris on a Plastic Health Care Surface. J Clin Microbiol. 2017 Oct;55(10):2996-3005.
Chowdhary A, Sharma C, Meis JF. Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog. 2017 May;13(5):e1006290.
Sharma C, Kumar N, Pandey R, Meis JF, Chowdhary A. Whole genome sequencing of emerging multidrug resistant Candida auris isolates in India demonstrates low genetic variation. New Microbes New Infect. 2016 Sep;13:77-82.
Chatterjee S, Alampalli SV, Nageshan RK, Chettiar ST, Joshi S, Tatu US. Draft genome of a commonly misdiagnosed multidrug resistant pathogen Candida auris. BMC Genomics. 2015 Sep 07;16(1):686.
Larkin E, Hager C, Chandra J, Mukherjee PK, Retuerto M, Salem I, Long L, Isham N, Kovanda L, Borroto-Esoda K, Wring S, Angulo D, Ghannoum M. The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation. Antimicrob Agents Chemother. 2017 May;61(5)
Johnson CJ, Davis JM, Huttenlocher A, Kernien JF, Nett JE. Emerging Fungal Pathogen Candida auris Evades Neutrophil Attack. mBio. 2018 Aug 21;9(4)
Navarro-Arias MJ, Hernández-Chávez MJ, García-Carnero LC, Amezcua-Hernández DG, Lozoya-Pérez NE, Estrada-Mata E, Martínez-Duncker I, Franco B, Mora-Montes HM. Differential recognition of Candida tropicalis, Candida guilliermondii, Candida krusei, and Candida auris by human innate immune cells. Infect Drug Resist. 2019;12:783-794.
Sherry L, Ramage G, Kean R, Borman A, Johnson EM, Richardson MD, Rautemaa-Richardson R. Biofilm-Forming Capability of Highly Virulent, Multidrug-Resistant Candida auris. Emerg Infect Dis. 2017 Feb;23(2):328-331.
Borman AM, Szekely A, Johnson EM. Comparative Pathogenicity of United Kingdom Isolates of the Emerging Pathogen Candida auris and Other Key Pathogenic Candida Species. mSphere. 2016 Jul-Aug;1(4)
Mitchell KF, Zarnowski R, Sanchez H, Edward JA, Reinicke EL, Nett JE, Mitchell AP, Andes DR. Community participation in biofilm matrix assembly and function. Proc Natl Acad Sci U S A. 2015 Mar 31;112(13):4092-7.
Dominguez EG, Zarnowski R, Choy HL, Zhao M, Sanchez H, Nett JE, Andes DR. Conserved Role for Biofilm Matrix Polysaccharides in Candida auris Drug Resistance. mSphere. 2019 Jan 02;4(1)
Romera D, Aguilera-Correa JJ, Gadea I, Viñuela-Sandoval L, García-Rodríguez J, Esteban J. Candida auris: a comparison between planktonic and biofilm susceptibility to antifungal drugs. J Med Microbiol. 2019 Sep;68(9):1353-1358.
Chowdhary A, Prakash A, Sharma C, Kordalewska M, Kumar A, Sarma S, Tarai B, Singh A, Upadhyaya G, Upadhyay S, Yadav P, Singh PK, Khillan V, Sachdeva N, Perlin DS, Meis JF. A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009-17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance. J Antimicrob Chemother. 2018 Apr 01;73(4):891-899.
Kean R, McKloud E, Townsend EM, Sherry L, Delaney C, Jones BL, Williams C, Ramage G. The comparative efficacy of antiseptics against Candida auris biofilms. Int J Antimicrob Agents. 2018 Nov;52(5):673-677.
Sarma S, Upadhyay S. Current perspective on emergence, diagnosis and drug resistance in Candida auris. Infect Drug Resist. 2017;10:155-165.
Choi HI, An J, Hwang JJ, Moon SY, Son JS. Otomastoiditis caused by Candida auris: Case report and literature review. Mycoses. 2017 Aug;60(8):488-492.
Kim MN, Shin JH, Sung H, Lee K, Kim EC, Ryoo N, Lee JS, Jung SI, Park KH, Kee SJ, Kim SH, Shin MG, Suh SP, Ryang DW. Candida haemulonii and closely related species at 5 university hospitals in Korea: identification, antifungal susceptibility, and clinical features. Clin Infect Dis. 2009 Mar 15;48(6):e57-61.
Emara M, Ahmad S, Khan Z, Joseph L, Al-Obaid I, Purohit P, Bafna R. Candida auris candidemia in Kuwait, 2014. Emerg Infect Dis. 2015 Jun;21(6):1091-2.
Magobo RE, Corcoran C, Seetharam S, Govender NP. Candida auris-associated candidemia, South Africa. Emerg Infect Dis. 2014 Jul;20(7):1250-1.
Anwar S, Glaser A, Acharya S, Yousaf F. Candida auris-an impending threat: A case report from home. Am J Infect Control. 2020 Nov;48(11):1407-1408.
Horton MV, Johnson CJ, Kernien JF, Patel TD, Lam BC, Cheong JZA, Meudt JJ, Shanmuganayagam D, Kalan LR, Nett JE. Candida auris Forms High-Burden Biofilms in Skin Niche Conditions and on Porcine Skin. mSphere. 2020 Jan 22;5(1)
Vila T, Sultan AS, Montelongo-Jauregui D, Jabra-Rizk MA. Candida auris: a fungus with identity crisis. Pathog Dis. 2020 Jun 01;78(4)
Yaman G, Akyar I, Can S. Evaluation of the MALDI TOF-MS method for identification of Candida strains isolated from blood cultures. Diagn Microbiol Infect Dis. 2012 May;73(1):65-7.

Volume: 3, No: 8, pp. 13255 – 13270
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6234
Wattal C, Oberoi JK, Goel N, Raveendran R, Khanna S. Matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS) for rapid identification of micro-organisms in the routine clinical microbiology laboratory. Eur J Clin Microbiol Infect Dis. 2017 May;36(5):807-812.

Grenfell RC, da Silva Junior AR, Del Negro GM, Munhoz RB, Gimenes VM, Assis DM, Rockstroh AC, Motta AL, Rossi F, Juliano L, Benard G, de Almeida Júnior JN. Identification of Candida haemulonii Complex Species: Use of ClinProTools(TM) to Overcome Limitations of the Bruker Biotyper(TM), VITEK MS(TM) IVD, and VITEK MS(TM) RUO Databases. Front Microbiol. 2016;7:940.

Wickes BL. Analysis of a Candida auris Outbreak Provides New Insights into an Emerging Pathogen. J Clin Microbiol. 2020 Mar 25;58(4)

Zhang SX, Carroll KC, Lewis S, Totten M, Mead P, Samuel L, Steed LL, Nolte FS, Thornberg A, Reid JL, Whitfield NN, Babady NE. Multicenter Evaluation of a PCR-Based Digital Microfluidics and Electrochemical Detection System for the Rapid Identification of 15 Fungal Pathogens Directly from Positive Blood Cultures. J Clin Microbiol. 2020 Apr 23;58(5)

Girard V, Mailler S, Chetry M, Vidal C, Durand G, van Belkum A, Colombo AL, Hagen F, Meis JF, Chowdhary A. Identification and typing of the emerging pathogen Candida auris by matrix-assisted laser desorption ionisation time of flight mass spectrometry. Mycoses. 2016 Aug;59(8):535-8.

Chaabane F, Graf A, Jequier L, Coste AT. Review on Antifungal Resistance Mechanisms in the Emerging Pathogen Candida auris. Front Microbiol. 2019;10:2788.

Fakhim H, Chowdhary A, Prakash A, Vaezi A, Dannaoui E, Meis JF, Badali H. In Vitro Interactions of Echinocandins with Triazoles against Multidrug-Resistant Candida auris. Antimicrob Agents Chemother. 2017 Nov;61(11)

Chowdhary A, Voss A, Meis JF. Multidrug-resistant Candida auris: 'new kid on the block' in hospital-associated infections? J Hosp Infect. 2016 Nov;94(3):209-212.

Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S, Bille J, Castagnola E, Cuenca-Estrella M, Donnelly JP, Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Flörl C, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ., ESCMID Fungal Infection Study Group. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012 Dec;18 Suppl 7:19-37.

Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD. Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Feb 15;62(4):409-17.

Fisher JF, Sobel JD, Kauffman CA, Newman CA. Candida urinary tract infections—treatment. Clin Infect Dis. 2011 May;52 Suppl 6:S457-66.

Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Feb 15;62(4):e1-50.

Mizusawa M, Miller H, Green R, Lee R, Durante M, Perkins R, Hewitt C, Simner PJ, Carroll KC, Hayden RT, Zhang SX. Can Multidrug-Resistant Candida auris Be Reliably Identified in Clinical Microbiology Laboratories? J Clin Microbiol. 2017 Feb;55(2):638-640.

Osei Sekyere J. Candida auris: A systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen. Microbiologyopen. 2018 Aug;7(4):e00578.

Morales-López SE, Parra-Giraldo CM, Ceballos-Garzón A, Martínez HP, Rodríguez GJ, Álvarez-Moreno CA, Rodríguez JY. Invasive Infections with Multidrug-Resistant Yeast Candida auris, Colombia. Emerg Infect Dis. 2017 Jan;23(1):162-164.

Chakrabarti A, Sood P, Rudramurthy SM, Chen S, Kaur H, Capoor M, Chhina D, Rao R, Eshwara VK, Xess I, Kindo AJ, Umabala P, Savio J, Patel A, Ray U, Mohan S, Iyer R, Chander J, Arora A, Sardana R, Roy I, Appalaraju B, Sharma A, Shetty A, Khanna N, Marak R, Biswas S, Das S, Harish BN, Joshi S, Mendiratta D. Incidence, characteristics and outcome of ICU-acquired candidemia in India. Intensive Care Med. 2015 Feb;41(2):285-95.

Calvo B, Melo AS, Perozo-Mena A, Hernandez M, Francisco EC, Hagen F, Meis JF, Colombo AL. First report of Candida auris in America: Clinical and microbiological aspects of 18 episodes of candidemia. J Infect. 2016 Oct;73(4):369-74.

Abdolrasouli A, Armstrong-James D, Ryan L, Schelenz S. In vitro efficacy of disinfectants utilised for skin decolonisation and environmental decontamination during a hospital outbreak with Candida auris. Mycoses. 2017 Nov;60(11):758-763

Cadnum JL, Shaikh AA, Piedrahita CT, Sankar T, Jencson AL, Larkin EL, Ghannoum MA, Donskey CJ. Effectiveness of Disinfectants Against Candida auris and Other Candida Species. Infect Control Hosp Epidemiol. 2017 Oct;38(10):1240-1243.

Cadnum JL, Shaikh AA, Piedrahita CT, Jencson AL, Larkin EL, Ghannoum MA, Donskey CJ. Relative Resistance of the Emerging Fungal Pathogen Candida auris and Other Candida Species to Killing by Ultraviolet Light. Infect Control Hosp Epidemiol. 2018 Jan;39(1):94-96.

Moore G, Schelenz S, Borman AM, Johnson EM, Brown CS. Yeasticidal activity of chemical disinfectants and antiseptics against Candida auris. J Hosp Infect. 2017 Dec;97(4):371-375.

Schelenz S, Hagen F, Rhodes JL, Abdolrasouli A, Chowdhary A, Hall A, Ryan L, Shackleton J, Trimlett R, Meis JF, Armstrong-James D, Fisher MC. First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob Resist Infect Control. 2016;5:35.

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13255 – 13270
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6234

كانديدا أوريس: مراجعة محدثة لتدخلات التمريض وبروتوكولات الإدارة

الملخص:

الخلفية: كانديدا أوريس (C. auris) هو فطر ناشئ مقاوم للأدوية المتعددة يشكل تهديدًا كبيرًا للصحة العامة على مستوى العالم، لا سيما في بيئات الرعاية الصحية. تم التعرف عليه لأول مرة في عام 2009، وقد انتشر بسرعة إلى أكثر من 35 دولة، مما تسبب في إصابات غازية بمعدلات وفيات مرتفعة، خاصة بين المرضى المثبطين مناعياً. إن مقاومته لعدة فئات من الأدوية المضادة للفطريات، والتشخيص الخاطئ بواسطة الأساليب التشخيصية القياسية، وقدرته على البقاء على الأسطح تعقد من إدارة هذا الكائن والسيطرة عليه.

الهدف: تهدف هذه المراجعة إلى تقديم نظرة محدثة عن *C. auris*، مع التركيز على وبائياته، وعلم الأمراض، وآليات مقاومة الأدوية، والإدارة السريرية. كما تبرز الدور الحيوي لتدخلات التمريض وبروتوكولات مكافحة العدوى في الوقاية من تفشي *C. auris* وإدارته.

المنهجية: تستعرض المراجعة الأدبيات الحالية حول *C. auris*، بما في ذلك مسبباته، وأنماط انتشاره، وعوامل قوته المرضية، وآليات مقاومته للأدوية المضادة للفطريات. كما تفحص التحديات التشخيصية، استراتيجيات العلاج، وبروتوكولات إدارة التمريض. تم إيلاء أهمية خاصة لتدابير مكافحة العدوى مثل النظافة الشخصية، تعقيم البيئة، وعزل المرضى لتقليل انتشار *C. auris* في بيئات الرعاية الصحية.

النتائج: يعد *C. auris* شديد الانتقال في بيئات المستشفيات، حيث تزيد مقاومته للأزولات والإيكينوكانديناتوالبولينيات من تعقيد العلاج. التشخيص المبكر باستخدام الأساليب الجزيئية المتقدمة، مثل MALDI-TOF MS وتسلسل الحمض النووي، أمر حاسم للإدارة الفعالة. تعد تدخلات التمريض، بما في ذلك الالتزام الصارم ببروتوكولات مكافحة العدوى، ورصد المرضى، والتعليم، أساسية للوقاية من الانتقال وتحسين نتائج المرضى.

الخاتمة: يمثل *C. auris* تحديًا كبيرًا بسبب مقاومته المتعددة للأدوية وقدرته على الانتشار بسرعة في بيئات الرعاية الصحية. إن اتباع نهج متعدد التخصصات، بما في ذلك التشخيص المبكر، والعلاج المستهدف بالأدوية المضادة للفطريات، وتدابير مكافحة العدوى القوية، أمر بالغ الأهمية لإدارة عدوى *C. auris*. يلعب الممرضون دورًا محوريًا في تنفيذ هذه الاستراتيجيات للحد من الانتقال وتحسين رعاية المرضى.

الكلمات المفتاحية: *Candida auris*، مقاومة الأدوية المتعددة، الإصابات المرتبطة بالمستشفيات، مقاومة الأدوية المضادة للفطريات، مكافحة العدوى، تدخلات التمريض، التشخيص الجزيئي.